Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Baraniuk

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
American Heart Journal|December 6, 2011
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationaleClaudia Zierold, Marjorie A Carlson, Udo C Obodo, et al.
American Heart Journal|December 1, 2012
Cardiovascular risk assessment: addition of CKD and race to the Framingham equationPaul E Drawz, Sarah Baraniuk, Barry R Davis, et al.
The Journal of Trauma and Acute Care Surgery|September 21, 2017
Outcomes after concomitant traumatic brain injury and hemorrhagic shock: A secondary analysis from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios trialSamuel M Galvagno, Erin E Fox, Savitri N Appana, et al.
Circulation|October 5, 2011
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Linda B Piller, Sarah Baraniuk, Lara M Simpson, et al.
Injury|July 6, 2014
Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementationSarah Baraniuk, Barbara C Tilley, Deborah J del Junco, et al.
Transfusion|April 1, 2015
Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trialDeborah J Novak, Yu Bai, Rhonda K Cooke, et al.
American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
JAMA|February 4, 2015
Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trialJohn B Holcomb, Barbara C Tilley, Sarah Baraniuk, et al.
JAMA|March 27, 2012
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trialEmerson C Perin, James T Willerson, Carl J Pepine, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
American Heart Journal|December 6, 2011
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationaleClaudia Zierold, Marjorie A Carlson, Udo C Obodo, et al.
American Heart Journal|December 1, 2012
Cardiovascular risk assessment: addition of CKD and race to the Framingham equationPaul E Drawz, Sarah Baraniuk, Barry R Davis, et al.
The Journal of Trauma and Acute Care Surgery|September 21, 2017
Outcomes after concomitant traumatic brain injury and hemorrhagic shock: A secondary analysis from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios trialSamuel M Galvagno, Erin E Fox, Savitri N Appana, et al.
Circulation|October 5, 2011
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)Linda B Piller, Sarah Baraniuk, Lara M Simpson, et al.
Injury|July 6, 2014
Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementationSarah Baraniuk, Barbara C Tilley, Deborah J del Junco, et al.
Transfusion|April 1, 2015
Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trialDeborah J Novak, Yu Bai, Rhonda K Cooke, et al.
American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
JAMA|February 4, 2015
Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trialJohn B Holcomb, Barbara C Tilley, Sarah Baraniuk, et al.
JAMA|March 27, 2012
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trialEmerson C Perin, James T Willerson, Carl J Pepine, et al.
Pageof 4